Though still in the investigational phase, HMN-372 represents a shift toward more selective immune therapies. By targeting axes specific to tumor cells while remaining largely absent from normal tissue, such agents aim to provide a more effective treatment with fewer side effects than broad-spectrum chemotherapy.

Current clinical milestones for this and similar molecules (like NPX372 or Ivonescimab ) are tracked through global registries like ClinicalTrials.gov and the UMIN Clinical Trials Registry .

The therapeutic potential of HMN-372 lies in its ability to inhibit specific signaling pathways that cancer cells use to proliferate.

: Its primary application has been explored for patients with NSCLC harboring specific mutations, such as EGFR Exon 20 insertion mutations .

: Clinical interest focuses on its "triple-threat" approach, which aims to block tumor growth while simultaneously preventing the cells from developing resistance to standard chemotherapy or earlier-generation inhibitors.